Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB): A new potential therapeutic target in atherosclerosis?

Pharmacological Reports

Volumn 62, Issue 5, 2010, Pages 778-783

  Da̧bek, Józefa ^a   Kułach, Andrzej ^a   Ga̧sior, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Atherosclerosis; Inflammation; Nuclear factor B; Therapy

Indexed keywords

CARVEDILOL; CILOSTAZOL; CURCUMIN; CYCLOPENTENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPOXOMICIN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LACTACYSTIN; PYRROLIDINE DITHIOCARBAMATE; RESVERATROL; SALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; VALIDATION PROCESS;

EID: 79551489425     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70338-8     Document Type: Review

References (51)

1. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD et al.: Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell, 2005, 8, 421-432.
2. Blackwell TS, Holden EP, Blackwell TR, Christman BW, Christman JW: Activation of NF-κB in rat lungs by treatment with endotoxin:modulation by treatment with N-acetylcysteine. J Immunol, 1996, 157, 1630-1637.
3. Bond M, Fabunmi RP, Baker AH, Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB FEBS Lett, 1998, 435, 29-34.
4. Bonizzi G, Karin M: The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 2004, 25, 280-288.
5. Brach MA, Henschler R, Mertelsmann RH, Herrmann F: Regulation of M-CSF expression by M-CSF: role of protein kinase C and ranscription factor NF kappa B. Pathobiology, 1991, 59, 284-288.
6. Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A et al.: Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol, 1997, 17, 1901-1909.
7. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M et al.: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest, 1996, 97, 1715-1722.
8. Cominacini L, Anselmi M, Garbin U, Fratta Pasini A, Stranieri C, Fusaro M, Nava C et al.: Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa B activation in patients with unstable angina. J Am Coll Cardiol, 2005, 46, 799-806.
9. Courtois G: The NF-κB signaling pathway in human genetic diseases. Cell Mol Life Sci, 2005, 62, 1682-1691
10. Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z: Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-κB inhibition. Am J Physiol Heart Circ Physiol, 2006, 291, H1694-1699.
11. Ellis RD, Limb GA, Thompson RP, Punchard NA: NF kappa B in Crohn's disease. Biochem Soc Trans, 1997, 25, 178S.
12. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, Monaco C et al.: Is NF-κB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis, 2002, 61 Suppl 2, ii13-18.
13. Gao L, Wang F, Wang B, Gong B, Zhang J, Zhang X, Zhao J: Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-κB-dependent downregulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther, 2006, 318, 53-58.
14. Ghosh S, Hayden MS: New regulators of NF-κB in inflammation. Nat Rev Immunol, 2008, 8, 837-848.
15. Hayden MS, West AP, Ghosh S: NF-κB and the immune response. Oncogene, 2006, 25, 6758-6780.
16. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J: ACE inhibitor quinapril reduces the arterial expression of NF-κB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol, 1998,153, 1825-1837.
17. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C et al.: Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res, 2003, 57, 168-177.
18. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H, Holschermann H: Statins differ in their ability to block NF-κB activation in human blood monocytes. Int J Clin Pharmacol Ther, 2003, 41, 397-401.
19. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, Clausen BE et al.: Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;112:1176-1185.
20. Karin M: How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene, 1999, 18, 6867-6874.
21. Karin M: The NF-κB activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am, 1998, 4, Suppl 1, S92-99.
22. Kopp E, Ghosh S: Inhibition of NFκB by sodium salicylate and aspirin. Science, 1994, 265, 956-959.
23. Kumar A, Boriek AM: Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J, 2003, 17, 386-396.
24. Kutuk O, Basaga H: Inflammation meets oxidation: NF-κB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med, 2003, 9, 549-557.
25. Li JJ, Fang CH, Chen MZ, Chen X, Lee SW: Activation of nuclear factor-κB and correlation with elevated plasma c-reactive protein in patients with unstable angina. Heart Lung Circ, 2004, 13, 173-178.
26. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-1143.
27. Lin R, Liu J, Peng N, Yang G, Gan W, Wang W: Lovastatin reduces nuclear factor κB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull, 2005, 28, 1630-1634.
28. Liuzzo G, Santamaria M, Biasucci LM, Narducci M, Colafrancesco V, Porto A, Brugaletta S et al.: Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein. J Am Coll Cardiol, 2007, 49, 185-194.
29. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F et al.: Protective role of interleukin-10 in atherosclerosis. Circ Res, 1999, 85, e17-e24.
30. Melisi D, Chiao PJ: NF-kappa B as a target for cancer therapy. Expert Opin Ther Targets, 2007, 11, 133-144.
31. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci USA, 1999, 96, 10403-10408.
32. Mirochnitchenko O, Inouye M: Effect of overexpression of human Cu,Zn superoxide dismutase in transgenic mice on macrophage functions. J. Immunol, 1996, 156, 1578-1586.
33. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J: Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, 1999, 147, 253-261.
34. Ortego M, Gomez-Hernandez A, Vidal C, Sanchez-Galan E, Blanco-Colio LM, Martin-Ventura JL, Tunon J et al.: HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol, 2005, 45, 468-475.
35. Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene, 1999, 18, 6853-6866.
36. Perkins ND: Regulation of NF-κB by atypical activators and tumour suppressors. Biochem Soc Trans, 2004, 32, 936-939.
37. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity, 1995, 2, 493-506.
38. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature, 2000, 403, 103-108.
39. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J: Angiotensin II activates nuclear transcription factor-κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant, 2001, 16 Suppl 1, 27-33.
40. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS: Role of transcriptional activation of I Bα in mediation of immunosuppression by glucocorticoids. Science, 1995, 270, 283-286.
41. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O, Gabler C et al.: ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-κB activity and AT1 receptor expression. Biochem Biophys Res Commun, 2004, 325, 532-540.
42. Schmitz ML: Function and activation of the transcription factor NF-κB in the response to toxins and pathogens. Toxicol Lett, 1995, 82-83, 407-411.
43. Schreck RK, Alberman K, Baeuerle PA: Nuclear factor κB: an oxidative stress-response transcription factor of eukaryotic cells. Free Radic Res Commun, 1992, 17, 221-237.
44. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46, 705-716.
45. Singh S, Aggarwal BB: Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem, 1995, 270, 24995-25000.
46. Sun Z, Andersson R: NF-κB activation and inhibition: a review. Shock, 2002, 18, 99-106.
47. Wang HR, Li JJ, Huang CX, Jiang H: Fluvastatin inhibits the expression of tumor necrosis factor-α and activation of nuclear factor-κB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta, 2005, 353, 53-60.
48. Xu HX, Li JJ, Li GS, Wang J, Li NX, Peng J: Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Acta Cardiol, 2007, 62, 607-613.
49. Yan J, Greer JM: NF-κB, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol Disord Drug Targets, 2008, 7, 536-557.
50. Yang SP, Ho LJ, Lin YL, Cheng SM, Tsao TP, Chang DM, Hsu YL et al.: Carvedilol, a new antioxidative β-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-κB activity. Cardiovasc Res, 2003, 59, 776-787.
51. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature, 1998, 396, 77-80.